• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Bayhealth Taps Syapse’s Real-World Data Platform to Optimize Oncology Data

by Fred Pennic 12/15/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Bayhealth Taps Syapse’s Real-World Data Platform to Optimize Oncology Data

What You Should Know:

– Syapse, a real-world evidence company that informs cancer care, announced a partnership with Bayhealth – central and southern Delaware’s largest healthcare system.

– Bayhealth will leverage Syapse’ multi-source real-world data platform to bring the latest in cancer diagnostics and treatments to Delaware patients, so that they can receive evidence-based care and match to potentially life-saving clinical trial opportunities.

Bringing Data-Driven Approach to Oncology Care

The proliferation of targeted oncology therapies has ushered in the precision medicine era, but if caregivers don’t have easy access to the information that allows them to determine the correct course of treatment for each individual patient, these advances fail to realize their full potential and patients aren’t able to reap the benefits. Due to historic oncology data collection, standardization and management challenges, and increasingly tight physician bandwidth, providers need a trusted and efficient way to analyze the most recent data regarding new diagnostics and treatments, so that each patient can be presented with the most appropriate, effective care plan for their unique healthcare needs.

The Syapse Learning Health Network (LHN) enables improved cancer care through collaboration. Leveraging the LHN, healthcare providers can learn which cancer treatments produced the best real-world outcomes in clinically and molecularly similar patients. Further, researchers can learn from real-world clinical, molecular, treatment, and outcomes data. These collaborations are enabled by a secure platform of shared de-identified data that is standardized and normalized across the LHN.

“Bayhealth is committed to providing community cancer care that is comprehensive, cutting edge, and personalized,” said Rishi Sawhney, MD, medical director of the Bayhealth Cancer Institute. “Our recently launched Precision Oncology Program focuses on the molecular profile of each individual cancer so that the most appropriate personalized treatment options may be considered. Our work with Syapse and the Syapse Learning Health Network will allow Bayhealth clinicians and researchers to leverage the latest technology to further advance personalized cancer care by increasing access to cutting-edge therapies and significantly expanding our clinical research efforts.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Oncology, Oncology Platform, Real World Evidence (RWE), Syapse

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |